Loading
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Previous close
$5.21
−$0.02 · -0.38%
Pre-market
$5.16
−$0.05 · -0.96%
Sep 8, 9:09 AM ET
Regular session · ET · Market data may be delayed.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Day range
Current $5.21
52-week range
Current $5.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
55
Mixed
Risk
63
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Day range
Current $5.21
52-week range
Current $5.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 590.08K USD | 2.47M USD | — | 766.28K USD | 827 USD |
| Cost of goods sold | 515.27K USD | 670.2K USD | 554 USD | 318.97K USD | 88 USD |
| Gross profit | 74.81K USD | 1.8M USD | −554 USD | 447.31K USD | 739 USD |
| Research and development | 147.01K USD | 104.65K USD | 7.41K USD | 228.75K USD | 123.63K USD |
| Selling, general, and administrative | 1.62M USD | 855.76K USD | 1.13M USD | 1.73M USD | 634.33K USD |
| Operating expenses | 7.45M USD | 3.66M USD | 1.14M USD | 2.24M USD | 785.8K USD |
| Interest income | 118.03K USD | 12.89K USD | 5.56K USD | 7.7K USD | — |
| Interest expense | 547.13K USD | 735.2K USD | — | 2.63K USD | — |
| Depreciation and amortization | 110.5K USD | 83.1K USD | 554 USD | 6.51K USD | 2.76K USD |
| Operating income | −7.38M USD | −1.87M USD | −1.14M USD | −1.79M USD | −785.06K USD |
| Net income | −7.71M USD | −6.25M USD | −4.3M USD | −1.8M USD | −784.74K USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 21, 2026 | 1:10 | — | — |
Stock split | Mar 10, 2026 | 1:6 | — | — |
Stock split | Jan 6, 2026 | 1:4 | — | — |
Stock split | Sep 2, 2025 | 2:7 | — | — |
Stock split | Mar 10, 2025 | 1:7 | — | — |
Stock split | Nov 27, 2024 | 1:200 | — | — |
Effective Aug 21, 2026
1:10
Effective Mar 10, 2026
1:6
Effective Jan 6, 2026
1:4
Effective Sep 2, 2025
2:7
Effective Mar 10, 2025
1:7
Effective Nov 27, 2024
1:200
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
